# **RESEARCH ARTICLE**

**Open Access** 

# Prognostic significance of cervical radiologic carotid artery invasion by lymph node on magnetic resonance imaging in nasopharyngeal carcinoma



Wenze Qiu<sup>1†</sup>, Xi Zhong<sup>2†</sup>, Jiali Jiang<sup>3†</sup>, Laiji Huang<sup>1</sup>, Jiansheng Li<sup>2</sup>, Ronghui Zheng<sup>1\*</sup>, Zhuochen Cai<sup>4,5\*</sup> and Yawei Yuan<sup>1\*</sup>

# **Abstract**

**Purpose** Carotid artery invasion (CAI) has been demonstrated to be an important prognosticator in some head and neck cancers. This study aimed to examine the prognostic value of radiologic CAI (rCAI) by cervical lymphadenopathy in nasopharyngeal carcinoma (NPC).

**Methods** NPC patients treated between January 2013 and December 2016 were included. Pre-treatment MRIs were reviewed for cervical rCAI according to the radiologic criteria. Univariate and multivariate models were constructed to assess the association between cervical rCAI and clinical outcomes. A new N classification system was proposed and compared to the 8th AJCC system.

**Results** The percentage of patients with MRI-positive lymph nodes was 84.7% (494/583), of whom cervical rCAI cases accounted for 42.3% (209/494). Cervical rCAI was associated with significantly poorer OS, DFS, DFFS and RFFS compared to non-rCAI (*P* < 0.05). Multivariate analyses confirmed that cervical rCAI was an independent prognosticator for DFS and DFFS, surpassing other nodal features, such as laterality, size, cervical node necrosis (CNN) and radiologic extranodal extension (rENE), while location of positive LNs remained independently associated with OS, DFS and DFFS. We propose a refined N classification: New\_N1: upper neck LNs only without cervical rCAI; New\_N2: upper neck LNs only with cervical rCAI; New\_N3: upper and lower LNs. The proposed classification broadened the differences in OS, DFS and DFFS between N1 and N2 disease, and achieved a higher c-index for DFS and DFFS.

**Conclusions** Cervical rCAI was an independent unfavorable indicator of NPC. Compared to the AJCC system, the proposed N category showed satisfactory stratification between N1 and N2 disease, and better prediction of distant metastasis and disease failure.

<sup>†</sup>Wenze Qiu, Xi Zhong, and Jiali Jiang contributed equally to this work.

\*Correspondence:
Ronghui Zheng
zhengronghui@gzhmu.edu.cn
Zhuochen Cai
caizc@sysucc.org.cn
Yawei Yuan
yuanyawei@gzhmu.edu.cn
Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Qiu et al. Cancer Imaging (2023) 23:26 Page 2 of 12

**Keywords** Nasopharyngeal carcinoma, Carotid artery invasion, Nodal staging system, Prognostication, Magnetic resonance imaging

# Introduction

Nasopharyngeal carcinoma (NPC), a tumor arising from the epithelial cells that cover the surface and line the nasopharynx [1], is characterized by an aggressive behavior with early spread to regional lymph nodes and a high likelihood of distant metastasis [2]. Accurate assessment of cervical lymph node status is critical for guiding treatment choices and predicting prognosis in patients with head and neck squamous cell carcinoma (HNSCC), including NPC [3].

The American Joint Committee on Cancer (AJCC) staging system (8th edition) [4] for NPC classically considers a combination of lymph node (LN) factors, including laterality, size, and level. Moreover, emerging evidence has shown that other nodal features, such as cervical node necrosis (CNN) [5–7], radiologic extranodal extension (rENE) [8, 9] and more than nine MRI-positive LNs [10], may contribute to the lower survival rates in patients with metastatic nodes from cancer of the nasopharynx.

Involvement of carotid artery by a primary neoplasm or adjacent lymph nodes is not only a poor prognostic indicator but also a potential contraindication to surgical resection in HNSCC [11, 12]. As for NPC, the extension of primary tumor to carotid sheath, a part of the parapharyngeal space (PPS), is defined as T2 disease and its prognostic influence on survival outcome has been widely demonstrated [13–15]. Furthermore, Chan et al. discovered that stage II recurrent NPC encasing the internal carotid artery had significantly higher opportunity of developing subsequent systemic metastasis, even after adequate resection of the tumor [16]. However, no studies have yet examined the prognostic value of cervical carotid artery invasion (CAI) by lymph node in treatment-naive patients with NPC.

The presence of cervical CAI is chiefly assessed by imaging instead of neck dissection because, unlike other head and neck cancers, NPC is typically treated with radiotherapy. Magnetic resonance imaging (MRI) has been recommended as the optimal method for assessing T and N classification in NPC patients before treatment according to the National Cancer Comprehensive Network (NCCN) guideline. The radiologic criteria of carotid artery invasion on MRI have been previously described [11, 12, 17, 18].

Therefore, we conducted this retrospective study to comprehensively evaluate the role of radiologic CAI (rCAI) by cervical lymphadenopathy in NPC patients on the basis of MRI findings.

# **Methods**

# Patient population

This retrospective study evaluated 583 consecutive patients with newly diagnosed, biopsy-proven, non-metastatic NPC, who received intensity-modulated radiotherapy (IMRT) at the Affiliated Cancer Hospital & Institute of Guangzhou Medical University between January 2013 and December 2016. All patients were scanned using MRI and restaged in accordance to the 8th edition of the AJCC staging system for NPC [4]. This study was approved by the Institutional Review Boards at the Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Signed informed consent was obtained from all patients before examination.

# MRI protocol

Pretreatment MRI was performed on a 1.5-T scanner with head and neck array coils. The examined area extended from the upper border of the orbit to the inferior margin of the sternal end of the clavicle. The detailed MR scanning protocol and acquisition parameters are shown in Table S1, which were described previously [19].

# Image assessment

Pre-treatment MRIs were reviewed by a radiologists (XZ) experienced in head and neck MRI blinded to clinical outcome. The diagnostic criteria for metastatic lymphadenopathy were: (1) retropharyngeal lymph nodes, cervical lymph nodes in the jugulodigastric region and any other cervical lymph nodes with a shortest axial diameter of 5 mm, 11 mm and 10 mm or greater, respectively; (2) groups of three or more borderline lymph nodes with a shortest axial diameter of 8 mm or greater; (3) lymph nodes of any size with rENE or necrosis [20, 21]. The features of rENE included the presence of indistinct nodal margins, irregular nodal capsular enhancement or infiltration into adjacent structures, such as muscles, neurovascular structures, parotid, or skin [22]. The equivocal/ uncertain cases were classified as rENE-. Definition of central necrosis on MR images was a focal area of high signal intensity on T2-weighted images or a focal area of low signal intensity on T1-weighted images with or without a surrounding rim of enhancement [23].

Until now, no consensus has been reached on standardization of imaging criteria for defining encasement of

Qiu et al. Cancer Imaging (2023) 23:26 Page 3 of 12

the carotid artery. In our study, any invasion of internal, external and common carotid artery by cervical lymph node was assessed using the following radiological criteria selected from literature [11, 12, 17, 18]: (1) circumference of lymph node attachment to the artery>180 degrees, (2) obliteration of the fat plane between the lymph node and the carotid artery, (3) deformation of the carotid artery, (4) length of contact between the carotid artery and lymph node > 30 mm. The combination of 2 or more findings was predictive of suspicious carotid artery invasion (Fig. 1).

To assess the intra/inter-rater reliability of cervical rCAI, MR scans of a subset of randomly selected cases were re-reviewed by the same radiologist (XZ) after a three-month interval and were also independently reviewed by a second radiologist (JL).


# Treatment and follow-up

The nasopharyngeal and neck tumors of all patients were treated using radical radiotherapy based on IMRT for the entire course. The primary NPC gross tumor volume was defined as the primary tumor observed during the clinical examination and imaging, and was given a total dose of 66-72 Gy in 30–33 fractions. The metastatic lymph node area was defined as the area with clinically and/or radiologically observed enlarged lymph nodes, and was given a total dose of 64-70 Gy in 30–33 fractions. During the study, institutional guidelines (based on the 7th edition AJCC cancer staging system [24]) recommended IMRT alone for stage I disease and concurrent chemoradiotherapy with or without neoadjuvant/adjuvant chemotherapy for stage II to IVB NPC. Salvage treatments

(such as reirradiation, chemotherapy and surgery) were given to patients with documented relapse or persistent disease. After completion of treatment, follow-up intervals were 3 months in the first 2 years, 3–6 months for the next 3–5 years and then annually.

# Statistical analysis

Baseline characteristics were compared between the rCAI vs. non-rCAI cohorts using Chi-square, Fisher's exact, or Wilcoxon-Mann Whitney test for categorical variables. Overall survival (OS; time from the day of treatment initiation until death from any cause), diseasefree survival (DFS; until failure or death from any cause, whichever occurred first), distant failure-free survival (DFFS; until distant metastasis), and regional failurefree survival (RFFS; until regional persistence/recurrence) were calculated with the Kaplan-Meier method, and differences were compared with the log-rank test. Univariate analysis was also conducted by using the logrank test. Multivariate analysis and the effect of N stage on risk for death, disease failure and distant failure were performed by using the Cox proportional hazards model. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were calculated. Intra- and inter-observer agreements for assessing rCAI vs. non-rCAI were calculated using Cohen's kappa test and kappa coefficient was calculated. The performances of the AJCC and the proposed N staging system were compared with the Harrell's concordance index (c-index). Two-tailed P values < 0.05 were considered statistically significant. Statistical analyses were performed using the Statistical Package for the



**Fig. 1** MRI scans of one patient showing lymph node metastases involving the carotid artery. **a-b** Axial contrast-enhanced T1WI and T2WI showing > 180 degree of encasement of the internal carotid artery with a blurred fat plane (black arrow) and < 180 degree of encasement of the external carotid artery (white arrow) at the left side. **c** Sagittal contrast-enhanced T1WI showing the length of carotid involvement at the left side, measuring 66.7 mm

Qiu et al. Cancer Imaging (2023) 23:26 Page 4 of 12

Social Sciences (SPSS) version 25.0 (IBM, Armonk, NY, USA) and R package (Version 4.0.3).

# **Results**

# **Patient population**

A total of 583 consecutive non-metastatic NPC patients were identified, of which 494 (84.7%) were lymph node-positive. The clinical characteristics of the 583 eligible patients are listed in Table 1. The male (n=424)-to-female (n=159) ratio was 2.7:1, and the median age was 47 years (range, 16–76 years).

The incidence of cervical rCAI in patients with positive lymph node metastases was 42.3% (209/494). The frequency of cervical rCAI increased with higher N-category: N1: 22.0% (44/200), N2: 41.5% (76/183), N3: 80.2% (89/111) and higher total stage: II: 16.0% (8/50), III: 34.9% (87/249), IV: 58.5% (114/195). Accordingly, more patients in the rCAI cohort received CCRT+NAC/AC (P=0.001). Compared with the non-rCAI cohort, the rCAI cases had more bilateral and lower cervical LNs, and rCAI was found in a higher proportion of>6 cm based on the largest LN dimension (all P < 0.001). In addition, LNs with rCAI were more likely to have a necrotic appearance and extranodal extension (both P < 0.001). Among patients with positive cervical lymph node metastases (n=435), rCAI was identified at level II (37.1%, 126/340), III (44.9%, 88/196), IV (23.8%, 10/42) on the right side and level II (34.6%, 120/347), III (48.0%, 98/204), IV (23.9%, 11/46) on the left side. rCAI was not found at level I, VA or VB (Table S2).

Median follow-up for the entire cohort was 52 (range, 5–101) months. Regional failure, distant failure, disease failure and deaths were detected in 8, 96, 125 and 67, respectively. Five-year RFFS, DFFS, DFS and OS were 98.4%, 82.0%, 76.8%, and 86.2%, respectively.

# Prognostic values of cervical rCAI in 494 patients with metastatic nodes

When compared to patients with non-rCAI, the rCAI cohort had a significantly inferior 5-years OS, DFS, DFFS and RFFS (all P < 0.05; Table S3 and Fig. 2). In univariate analysis (Table S3), N stage, the location of positive LNs, rENE and cervical rCAI were associated with OS, DFS, DFFS and RFFS (all P < 0.05). Total stage, the laterality of positive LNs were related with OS, DFS and DFFS (all P < 0.05), but not RFFS. The size of positive LNs and CNN were in relation to DFS and DFFS (all P < 0.05). T stage was only associated with OS (all P < 0.05).

In multivariate analysis (Table 2), after adjusting for several potentially clinical confounding factors (i.e. gender, age, T stage and chemotherapy) and other nodal features (i.e. the laterality, location, size of positive LNs, CNN and rENE), cervical rCAI was independently

associated with DFS (P=0.010) and DFFS (P=0.045), but not OS (P=0.313). Additionally, location of positive LNs was an independent prognostic factor for OS (P=0.007), DFS (P=0.008) and DFFS (P=0.012). rENE was an independent prognostic factor for OS (P=0.043) and DFFS (P=0.045), but not DFS (P=0.053). The laterality, size of positive LNs and CNN were not independent prognostic factors for OS, DFS or DFFS.

# A proposed N classification system

Based on the results above, we proposed a revised N classification system that included the location of positive LNs and cervical rCAI: New\_N1: upper neck LNs only without cervical rCAI (n = 265); New\_N2: upper neck LNs only with cervical rCAI (n = 143); New\_N3: upper and lower LNs (n=86). A change in N3 stage mainly occurred in the 4.3% of patients (25 of 583) with > 6 cm LNs on the upper neck only, of whom 0.3% (2 of 583) without cervical rCAI were downstaged to N1 and 3.9% (23 of 583) with cervical rCAI were downstaged to N2. As shown in Fig. 3, our revised N staging system showed satisfactory stratification between classification N1 and N2 in DFS and DFFS; meanwhile, survival curves of DFS and DFFS between N2 and N3 patients remained separated significantly. However, neither of these two N category systems could significantly separate N0 and N1 in OS, DFS and DFFS. To assess the hazard ratios of the AJCC system and proposed N staging system, multivariate analysis was performed adding confounding factors of age, gender, T stage and chemotherapy. Results showed that the hazard ratio discrimination of OS, DFS and DFFS between N1 and N2 disease were improved (Table 3). Compared with the AJCC system, the c-index of the proposed N staging system showed a significant improvement for predicting DFS (0.721 vs. 0.671, P=0.007), and DFFS (0.737 vs. 0.698, P = 0.043), but not OS (0.690 vs. 0.665, P = 0.177).

# Intra- and inter-observer variation of cervical rCAI assessment

Based on a power calculation ( $\geq$  80% power to detect significant discordance in cervical rCAI), 80 cases were randomly selected for intra- and inter-observer assessment. The intra- and inter-observer kappa for cervical rCAI was 0.812 and 0.757, respectively.

# **Discussion**

For head and neck squamous cell carcinoma, such as the cancer of oral cavity, oropharynx, hypopharynx and larynx, carotid artery involvement by primary tumor masses has been classified as T4b disease and is considered an unresectable disease based on the NCCN guideline [25]. For NPC, a unique type of head and neck cancer typically

Qiu et al. Cancer Imaging (2023) 23:26 Page 5 of 12

**Table 1** Clinical characteristics of 583 nasopharyngeal carcinoma patients

| Variables                           | N0 (n = 89, 15.3%) | N + patients ( $n = 494$ ,            | 84.7%)                |         |
|-------------------------------------|--------------------|---------------------------------------|-----------------------|---------|
|                                     |                    | Non-rCAI (n = 285, 57.7%)             | rCAI (n = 209, 42.3%) | Р       |
| Gender                              |                    |                                       |                       | 0.007   |
| Male                                | 68 (76.4)          | 192 (67.4)                            | 164 (78.5)            |         |
| Female                              | 21 (23.6)          | 93 (32.6)                             | 45 (21.5)             |         |
| Age                                 |                    |                                       |                       | 0.911   |
| ≤47 years                           | 45 (50.6)          | 146 (51.2)                            | 106 (50.7)            |         |
| >47 years                           | 44 (49.4)          | 139 (48.8)                            | 103 (49.3)            |         |
| Histologic type                     |                    |                                       |                       | 0.646   |
| KSCC                                | 0                  | 1 (0.4)                               | 2 (1.0)               |         |
| NKDC                                | 1 (1.1)            | 13 (4.6)                              | 11 (5.3)              |         |
| NKUC                                | 88 (98.9)          | 271 (95.0)                            | 196 (93.7)            |         |
| T stage                             |                    |                                       |                       | 0.701   |
| T1                                  | 7 (7.9)            | 20 (7.0)                              | 16 (7.7)              |         |
| T2                                  | 27 (30.3)          | 70 (24.5)                             | 56 (26.7)             |         |
| T3                                  | 38 (42.7)          | 131 (46.0)                            | 99 (47.4)             |         |
| T4                                  | 17 (19.1)          | 64 (22.5)                             | 38 (18.2)             |         |
| N stage                             |                    |                                       |                       | < 0.001 |
| N0                                  | 89 (100)           |                                       |                       |         |
| N1                                  |                    | 156 (54.7)                            | 44 (21.1)             |         |
| N2                                  |                    | 107 (37.5)                            | 76 (36.4)             |         |
| N3                                  |                    | 22 (7.8)                              | 89 (42.5)             |         |
| Total stage                         |                    | , ,                                   | , ,                   | < 0.001 |
| 1                                   | 7 (7.9)            |                                       |                       |         |
| II                                  | 27 (30.3)          | 42 (14.7)                             | 8 (3.8)               |         |
| III                                 | 38 (42.7)          | 162 (56.8)                            | 87 (41.6)             |         |
| IV                                  | 17 (19.1)          | 81 (28.5)                             | 114 (54.5)            |         |
| Chemotherapy                        | , ,                | , ,                                   | , ,                   | 0.001   |
| RT alone                            | 10 (11.2)          |                                       |                       |         |
| CCRT alone                          | 32 (36.0)          | 44 (15.4)                             | 12 (5.7)              |         |
| CCRT + NAC/AC                       | 47 (52.8)          | 241 (84.6)                            | 197 (94.3)            |         |
| Laterality of cervical positive LNs | <b>(</b>           | (* ***)                               |                       | < 0.001 |
| RLNs only                           | =                  | 59 (20.7)                             | 0 (0)                 |         |
| Unilateral                          | -                  | 100 (35.1)                            | 74 (35.4)             |         |
| Bilateral                           | =                  | 126 (44.2)                            | 135 (64.6)            |         |
| Location of positive LNs            |                    | ,                                     | ,                     | < 0.001 |
| Upper neck only                     | _                  | 265 (93.0)                            | 143 (68.4)            |         |
| Upper + lower neck                  | _                  | 20 (7.0)                              | 66 (31.6)             |         |
| Size of positive LNs                |                    | 20 (7.0)                              | 00 (5 1.0)            | < 0.001 |
| ≤6 cm                               | _                  | 279 (97.9)                            | 156 (74.6)            |         |
| >6 cm                               | =                  | 6 (2.1)                               | 53 (25.4)             |         |
| CNN                                 |                    | ♥ (E)                                 | 22 (=2)               | < 0.001 |
| No                                  | =                  | 236 (82.8)                            | 87 (41.6)             | . 0.001 |
| Yes                                 | =                  | 49 (17.2)                             | 122 (58.4)            |         |
| rENE                                |                    | · · · · · · · · · · · · · · · · · · · | . 22 (39. 1)          | < 0.001 |
| No                                  | =                  | 157 (55.1)                            | 4 (1.9)               | \ 0.001 |
| Yes                                 | _                  | 128 (44.9)                            | 205 (98.1)            |         |

Abbreviations: rCAI radiological carotid artery invasion, KSCC keratinizing squamous cell carcinoma, NKDC non-keratinizing differentiated carcinoma, NKUC non-keratinizing undifferentiated carcinoma, RT radiotherapy, CCRT concurrent chemoradiotherapy, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, LN lymph node, RLN retropharyngeal lymph node, CNN cervical node necrosis, rENE radiological extranodal extension

Qiu et al. Cancer Imaging (2023) 23:26 Page 6 of 12




Fig. 2 The Kaplan–Meier curves of overall **a**, disease-free **b**, distant failure-free **c** and regional failure-free **d** survival in NPC patients with or without cervical rCAI

treated with radiotherapy, the impact of carotid artery involvement by cervical lymphadenopathy on the prognosis warrants thorough investigation.

For the first time, we observed a high incidence of cervical rCAI (42.3%) in patients with NPC and nodal metastasis. Cervical rCAI was only identified at level II, III and IV by metastatic lymph nodes, probably due to their location around the carotid artery [12, 26]. We further described the relationship between the cervical rCAI and NPC patients' survival, and found that it is a predominant independent indicator for DFS and DFFS in NPC patients, outweighing other nodal features, such as laterality, size, CNN and rENE.

Distant metastasis has become the greatest challenge for NPC treatment owing to the substantial improvement in locoregional control [27]. A common pattern for carcinomas is that regional LNs are the first sites to develop metastases through the lymphatic pathway orderly [28]. However, the potential role of primary tumor mass or metastatic LNs as a route for hematogenous spread should not be ignored. Plenty of studies regarding the

parapharyngeal space (PPS) extension have discover that distant metastasis is more likely in the presence of obvious involvement of the poststyloid compartment, which is probably due to tumor directly invading the blood vessels in the carotid sheath and increasing the risk of hematogeneous dissemination [13–15]. Similarly, in our study, metastatic LNs with CAI might denote the biological aggressiveness of cancer clones via blood stream, which facilitates systemic metastasis in NPC.

In the present study, the prognostic significance of several MRI identified nodal features, including laterality, location, size, CNN and rENE, were evaluated comprehensively. In consistent with the results of prior researches [5–9], all of the nodal factors mentioned above were associated with survival according to univariate analysis. After adjustment for potentially clinical confounding factors (i.e. gender, age, T stage and chemotherapy) and other nodal features (i.e. the laterality, location, size, CNN and rENE), multivariate analysis demonstrated that the presence of cervical rCAI still had increased HRs for distant metastasis and disease failure.

Qiu et al. Cancer Imaging (2023) 23:26 Page 7 of 12

**Table 2** Multivariate analysis in 494 patients with metastatic nodes

| Variables                           | OS                                      |         | DFS                                     |       | DFFS              |       |
|-------------------------------------|---|---------|---|-------|-------------------|-------|
|                                     | HR (95% CI)                             | P       | HR (95% CI)                             | P     | HR (95% CI)       | P     |
| Gender                              |   | 0.158   |   | 0.662 |                   | 0.708 |
| Male                                | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Female                              | 1.47 (0.86-2.52)                        |         | 1.10 (0.72-1.66)                        |       | 0.91 (0.55-1.50)  |       |
| Age                                 |   | 0.089   |   | 0.018 |                   | 0.049 |
| ≤47 years                           | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| >47 years                           | 1.56 (0.93-2.60)                        |         | 1.56 (1.08-2.26)                        |       | 1.53 (1.00-2.33)  |       |
| T stage                             |   | < 0.001 |   | 0.011 |                   | 0.067 |
| T1                                  | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| T2                                  | 4.42 (0.57-34.38)                       | 0.156   | 2.67 (0.93-7.68)                        | 0.069 | 2.10 (0.71-6.18)  | 0.178 |
| T3                                  | 4.61 (0.62-34.46)                       | 0.137   | 2.74 (0.98-7.66)                        | 0.055 | 2.20 (0.78-6.23)  | 0.139 |
| T4                                  | 19.72 (2.64–147.48)                     | 0.004   | 4.71 (1.63-13.61)                       | 0.004 | 3.60 (1.22-10.63) | 0.021 |
| Chemotherapy                        |   | 0.051   |   | 0.799 |                   | 0.924 |
| CCRT alone                          | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| CCRT + NAC/AC                       | 0.47 (0.22-1.00)                        |         | 0.92 (0.47-1.79)                        |       | 0.96 (0.43-2.14)  |       |
| Laterality of cervical positive LNs |   | 0.050   |   | 0.185 |                   | 0.050 |
| RLNs only                           | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Unilateral                          | 0.47 (0.13–1.72)                        | 0.252   | 0.74 (0.26–2.06)                        | 0.559 | 0.41 (0.12–1.40)  | 0.155 |
| Bilateral                           | 1.02 (0.29–3.55)                        | 0.974   | 1.08 (0.39–2.98)                        | 0.882 | 0.72 (0.22–2.41)  | 0.594 |
| Location of positive LNs            |   | 0.007   |   | 0.008 |                   | 0.012 |
| Upper neck only                     | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Upper + lower neck                  | 2.21 (1.24–3.93)                        |         | 1.77 (1.16–2.70)                        |       | 1.84 (1.14–2.96)  |       |
| Size of positive LNs                |   | 0.937   |   | 0.202 |                   | 0.140 |
| ≤6 cm                               | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| >6 cm                               | 0.97 (0.44–2.12)                        |         | 1.39 (0.84–2.30)                        |       | 1.50 (0.88–2.58)  |       |
| CNN                                 |   | 0.468   |   | 0.586 |                   | 0.637 |
| No                                  | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Yes                                 | 0.81 (0.45–1.44)                        |         | 0.89 (0.59–1.35)                        |       | 1.12 (0.70–1.79)  |       |
| rENE                                | ,                                       | 0.043   | , | 0.053 | (,                | 0.045 |
| No                                  | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Yes                                 | 2.50 (1.03–6.08)                        |         | 2.02 (0.99–4.12)                        |       | 2.58 (1.02–6.51)  |       |
| Cervical rCAI                       | , | 0.313   | · ( · -/                                | 0.010 |                   | 0.045 |
| No                                  | 1 (reference)                           |         | 1 (reference)                           |       | 1 (reference)     |       |
| Yes                                 | 1.40 (0.73–2.70)                        |         | 1.91 (1.17–3.12)                        |       | 1.79 (1.01–3.17)  |       |

Abbreviations: OS overall survival, DFS disease-free survival, DFFS distant failure-free survival, HR hazard ratio, CI confidence interval, CCRT concurrent chemoradiotherapy, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, LN lymph node, RLN retropharyngeal lymph node, CNN cervical node necrosis, rENE radiological extranodal extension, rCAI radiological carotid artery invasion

Lower cervical LNs remained significant for OS, DFS and DFFS. rENE was still an independent prognostic factor for OS and DFFS. The laterality, size and CNN were not independent prognostic factors for survival any more.

This can be explained by the following reasons. ENE has been shown to contribute to disease progression in head and neck cancers, including NPC, for its tendency to increase the risk of tumor cell entering into blood stream [8, 9, 29–31]. Thus, invasion of the carotid artery, as one of the most important episodes of ENE, may reflect the impact of ENE on distant

metastasis directly. Previous studies also have demonstrated that LN size and laterality seem less important in predicting prognosis when taking into consideration other nodal features, such as nodal level, or the number of positive LNs [10, 32]. The reported proportion of NPC patients with LNs greater than 6 cm based on cross-sectional imaging only ranges from 1.4% to 2.7% [10, 32]. While in our study, nodal size was measured by the largest dimension, irrespective of the measurement plane according to AJCC staging system [4], thus a higher incidence of > 6 cm LNs (11.9%; 59 of 494) was

Qiu et al. Cancer Imaging (2023) 23:26 Page 8 of 12




Fig. 3 Overall (A, a), disease-free (B, b) and distant failure-free (C, c) survival for each N category as defined by the 8th edition of the AJCC N staging system (A-C) and the proposed N staging system (a-c)

observed, which is similar to Zhou's study (8.8%; 31 of 354) [33]. It is reasonable to speculate that larger LNs are prone to encase the artery and allow a longer contact between the lymph node mass and carotid artery,

which are indirect signs of carotid invasion. Li et al. [32] found that laterality remained an independent factor for DFFS and DFS when multivariate analysis was performed in NPC patients without level IV, Vb,

 Table 3
 Effect of different N stages on the risk of survival outcomes

| N stage | N stage AJCC system |       |                   |         |                   |         | Proposed system          |         |                          |         |                           |         |
|---------|---------------------|-------|-------------------|---------|-------------------|---------|--------------------------|---------|--------------------------|---------|---------------------------|---------|
|         | OS                  |       | DFS               |         | DFFS              |         | os                       |         | DFS                      |         | DFFS                      |         |
|         | HR (95% CI)         | Ь     | HR (95% CI)       | Ь       | HR (95% CI)       | ٩       | HR (95% CI)              | Ф       | HR (95% CI)              | Ь       | HR (95% CI)               | ٩       |
| 0<br>N  | 1 (reference)       |       | 1 (reference)     |         | 1 (reference)     |         | 1 (reference)            |         | 1 (reference)            |         | 1 (reference)             |         |
| Z       | 2.50 (0.72-8.71)    | 0.150 | 1.66 (0.75–3.65)  | 0.208   | 1.52 (0.61–3.79)  | 0.370   | 2.62 (0.77–8.91)         | 0.123   | 1.38 (0.63-3.03)         | 0.419   | 0.419 1.30 (0.53–3.23)    | 0.569   |
| N2      | 4.02 (1.18–13.69)   | 0.026 | 2.29 (1.05-4.98)  | 0.038   | 2.16 (0.88–5.33)  | 0.093   | 4.39 (1.26–15.34)        | 0.020   | 3.53 (1.62-7.71)         | 0.002   | 3.39 (1.38–8.31)          | 0.008   |
| N3      | 7.72 (2.26–26.44)   | 0.001 | 4.97 (2.28–10.83) | < 0.001 | 5.41 (2.22–13.16) | < 0.001 | <0.001 9.48 (2.75–32.69) | < 0.001 | <0.001 5.58 (2.52–12.38) | < 0.001 | < 0.001 5.88 (2.37–14.61) | < 0.001 |

Abbreviations: AJCC American Joint Committee on Cancer, OS overall survival, DFS disease-free survival, DFFS distant failure-free survival, HR hazard ratio, CI confidence interval

Qiu et al. Cancer Imaging (2023) 23:26 Page 10 of 12

or supraclavicular fossa (SCF) involvement, suggesting that nodal level was of primary prognostic significance, with laterality of secondary importance.

In this study, the major limitation of the AJCC N staging system was that it could not separate survival curves between classification N1 and N2 NPC patients, which is consistent with the result of a largescale multicenter study [34]. Intriguingly, when N2 and N1 are classified according to upper neck LNs only with or without cervical rCAI, the survival curves showed satisfactory stratification between them, with the differences of DFS and DFFS reaching statistical significance. Therefore, we propose a new N classification based on the location of positive LNs and cervical rCAI to refine AJCC\_N as follows: New\_N1: upper neck LNs only without cervical rCAI; New\_N2: upper neck LNs only with cervical rCAI; New\_N3: upper and lower LNs. On one hand, the lower level of LNs remained incorporated in the proposed staging system (New\_N3) for its strong prognostic significance and proximity to the thoracic duct, which possibly mediates systemic dissemination via lymph-venous conjunction [35]. On the other hand, LNs greater than 6 cm was excluded from the N classification criteria due to its lack of significance as an independent prognostic factor. Thus, 25 patients with > 6 cm LNs on the upper neck only were downstaged to New\_N1 (2 without cervical rCAI) or New N2 (23 with cervical rCAI). The predictive power of the proposed system appeared to be improved over that of the AJCC (8th edition) staging system regarding the risk of distant metastasis and disease failure with a higher c-index. Finally, we were capable of achieving good intra-observer and inter-observer reliability for cervical rCAI, supporting consideration to include this variable in clinical N classification.

Several limitations should be noted in this study. First, all patients enrolled were from the endemic region where the predominant histology was nonkeratinizing differentiated carcinoma. Whether or not cervical rCAI has the similar clinical implication in regions where keratinising carcinoma dominates is yet to be elucidated. Second, the pathologic confirmation of rCAI was unavailable in patients with NPC, who were typically treated with radiotherapy rather than surgery. Third, well-known prognostic indicators such as LN multiplicity, nodal volume and Epstein-Barr virus (EBV) DNA were not included in this study; it is yet unknown if incorporating these factors will alter the conclusions of this study. Finally, this is a retrospective study and validation of our results is needed in future data, especially in large sample, multicenter and prospective studies.

# **Conclusions**

In conclusion, cervical rCAI was an independent unfavorable indicator of NPC. Compared to the AJCC system, the proposed N category showed satisfactory stratification between N1 and N2 disease, and better prediction of distant metastasis and disease failure.

#### Abbreviations

AC Adjuvant chemotherapy

AJCC American Joint Committee on Cancer rCAI Radiologic carotid artery invasion CCRT Concurrent chemoradiotherapy

CI Confidence interval
c-index Concordance index
CNN Cervical node necrosis
DFFS Distant failure-free survival
DFS Disease-free survival
EBV Epstein-Barr virus

rENE Radiologic extranodal extension
HNSCC Head and neck squamous cell carcinoma

HR Hazard ratio

IMRT Intensity-modulated radiotherapy
KSCC Keratinizing squamous cell carcinoma

LN Lymph node

MRI Magnetic resonance imaging NAC Neoadjuvant chemotherapy

NCCN National Cancer Comprehensive Network
NKDC Non-keratinizing differentiated carcinoma
NKUC Non-keratinizing undifferentiated carcinoma

NPC Nasopharyngeal carcinoma

OS Overall survival
PPS Parapharyngeal space
RFFS Regional failure-free survival
RLN Retropharyngeal lymph node
SCF Supraclavicular fossa

SPSS Statistical Package for the Social Sciences

WHO World Health Organization

# **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40644-023-00544-z.

Additional file 1.
Additional file 2.
Additional file 3.

# Acknowledgements

Not applicable.

# Authors' contributions

Yawei Yuan, Zhuochen Cai and Ronghui Zheng designed the study, performed most of the investigations, and data analysis. Laiji Huang and Jiansheng Li contributed significantly to analysis and manuscript preparation. Wenze Qiu provided data and wrote the manuscript. Xi Zhong and Jiali Jiang reviewed and edited the manuscript. All authors read and approved the manuscript.

#### **Funding**

This study was funded by grants from the National Natural Science Foundation of China (No. 82002858), Guangzhou Key Medical Discipline Construction Project and Key Clinical Technology of Guangzhou (2019ZD17), and Guangdong Basic and Applied Basic Research Foundation (2021A1515110607).

Qiu et al. Cancer Imaging (2023) 23:26 Page 11 of 12

#### Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

#### **Declarations**

# Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Boards at the Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Informed consent was obtained from all individual participants included in

#### Consent for publication

Not applicable.

the study.

#### Competing interests

The authors have no relevant financial or non-financial interests to disclose.

#### **Author details**

<sup>1</sup>Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China. <sup>2</sup>Department of Radiology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China. <sup>3</sup>Health Ward, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China. <sup>4</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong, China. <sup>5</sup>Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong, China.

Received: 20 September 2022 Accepted: 7 March 2023 Published online: 13 March 2023

#### References

- Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80.
- Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33:3356–64.
- Mack MG, Rieger J, Baghi M, Bisdas S, Vogl TJ. Cervical lymph nodes. Eur J Radiol. 2008;66:493–500.
- Amin MB, Edge SB, Greene FL, editors. AJCC Cancer Staging Manual. 8th ed. New York NY: Springer; 2017.
- Lan M, Huang Y, Chen CY, Han F, Wu SX, Tian L, et al. Prognostic value of cervical nodal necrosis in nasopharyngeal carcinoma: analysis of 1800 patients with positive cervical nodal metastasis at MR imaging. Radiology. 2015;276:526-644.
- Luo Y, Ren J, Zhou P, Gao Y, Yang G, Lang J. Cervical nodal necrosis is an independent survival predictor in nasopharyngeal carcinoma: an observational cohort study. Onco Targets Ther. 2016;9:6775–83.
- Zhang LL, Li JX, Zhou GQ, Tang LL, Ma J, Lin AH, et al. Influence of cervical node necrosis of different grades on the prognosis of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. J Cancer. 2017;8:959–66.
- Ai QY, King AD, Poon DMC, Mo FKF, Hui EP, Tong M, et al. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncol. 2019;88:124–30.
- Lu T, Hu Y, Xiao Y, Guo Q, Huang SH, O'Sullivan B, et al. Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. Oral Oncol. 2019;99: 104438.
- Ma H, Liang S, Cui C, Zhang Y, Xie F, Zhou J, et al. Prognostic significance of quantitative metastatic lymph node burden on magnetic resonance imaging in nasopharyngeal carcinoma: a retrospective study of 1224 patients from two centers. Radiother Oncol. 2020;151:40–6.
- 11. Chung EJ, Kwon KH, Yoon DY, Cho SW, Kim EJ, Rho YS. Clinical outcome analysis of 47 patients with advanced head and neck cancer

- with preoperative suspicion of carotid artery invasion. Head Neck. 2016;38(Suppl 1):E287–92.
- 12. Teymoortash A, Rassow S, Bohne F, Wilhelm T, Hoch S. Clinical impact of radiographic carotid artery involvement in neck metastases from head and neck cancer. Int J Oral Maxillofac Surg. 2016;45:422–6.
- Tang LL, Chen L, Mao YP, Li WF, Sun Y, Liu LZ, et al. Comparison of the treatment outcomes of intensity-modulated radiotherapy and twodimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiother Oncol. 2015;116:167–73.
- 14. Cui C, Li H, Ma H, Dong A, Xie F, Liang S, et al. Staging of T2 and T3 nasopharyngeal carcinoma: proposed modifications for improving the current AJCC staging system. Cancer Med. 2020;9:7572–9.
- Huang W, Quan T, Zhao Q, Li S, Cai Y, Zhou J, et al. MRI of nasopharyngeal carcinoma: parapharyngeal subspace involvement has prognostic value and influences T-staging in the IMRT era. Eur Radiol. 2022;32:262–71.
- Chan JYW, Wong STS, Wei WI. Stage II recurrent nasopharyngeal carcinoma: prognostic significance of retropharyngeal nodal metastasis, parapharyngeal invasion, and carotid encasement. Head Neck. 2018;40:103–10.
- Yousem DM, Hatabu H, Hurst RW, Seigerman HM, Montone KT, Weinstein GS, et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology. 1995;195:715–20.
- Pons Y, Ukkola-Pons E, Clement P, Gauthier J, Conessa C. Relevance of 5 different imaging signs in the evaluation of carotid artery invasion by cervical lymphadenopathy in head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:775–8.
- Zhong X, Li L, Lu B, Zhang H, Huang L, Lin X, et al. Differentiation of cervical spine osteoradionecrosis and bone metastasis after radiotherapy detected by bone scan in patients with nasopharyngeal carcinoma: role of magnetic resonance imaging. Front Oncol. 2020;10:15.
- King AD, Ahuja AT, Leung SF, Lam WW, Teo P, Chan YL, et al. Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck. 2000;22:275–81.
- 21. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177:379–84.
- King AD, Tse GM, Yuen EH, To EW, Vlantis AC, Zee B, et al. Comparison of CT and MR imaging for the detection of extranodal neoplastic spread in metastatic neck nodes. Eur J Radiol. 2004;52:264–70.
- 23. King AD, Tse GM, Ahuja AT, Yuen EH, Vlantis AC, To EW, et al. Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging, and US. Radiology. 2004;230:720–6.
- 24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. New York: Springer; 2010.
- National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2023). In. https://www.nccn.org/professionals/physician\_gls/pdf/head-and-neck.pdf. December 20, 2022.
- Hiyama T, Kuno H, Nagaki T, Sekiya K, Oda S, Fujii S, et al. Extra-nodal extension in head and neck cancer: how radiologists can help staging and treatment planning. Jpn J Radiol. 2020;38:489–506.
- Sun XS, Liu SL, Luo MJ, Li XY, Chen QY, Guo SS, et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Phys. 2019;105:581–90.
- Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573–83.
- Dunne AA, Muller HH, Eisele DW, Kessel K, Moll R, Werner JA. Metaanalysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients. Eur J Cancer. 2006;42:1863–8.
- 30. Chin O, Yu E, O'Sullivan B, Su J, Tellier A, Siu L, et al. Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiother Oncol. 2021;165:94–102.
- Mao Y, Wang S, Lydiatt W, Shah JP, Colevas AD, Lee AWM, et al. Unambiguous advanced radiologic extranodal extension determined by
  MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential
  improvement for future editions of N category systems. Radiother Oncol.
  2021;157:114–21.

Qiu et al. Cancer Imaging (2023) 23:26 Page 12 of 12

- 32. Li WF, Sun Y, Mao YP, Chen L, Chen YY, Chen M, et al. Proposed lymph node staging system using the International Consensus Guidelines for lymph node levels is predictive for nasopharyngeal carcinoma patients from endemic areas treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:249–56.
- Zhou X, Ou X, Yang Y, Xu T, Shen C, Ding J, et al. Quantitative metastatic lymph node regions on magnetic resonance imaging are superior to AJCC N classification for the prognosis of nasopharyngeal carcinoma. J Oncol. 2018;2018:9172585.
- 34. OuYang PY, Xiao Y, You KY, Zhang LN, Lan XW, Zhang XM, et al. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017;72:65–72.
- 35. Skandalakis JE, Skandalakis LJ, Skandalakis PN. Anatomy of the lymphatics. Surg Oncol Clin N Am. 2007;16:1–16.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$  thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

**Learn more** biomedcentral.com/submissions

